Doctors told not to routinely prescribe molnupiravir for mild COVID-19
The National Clinical Evidence Taskforce released updated guidance for GPs on Friday
GPs are being advised against the routine use of molnupiravir to treat patients with mild COVID-19 following evidence the antiviral failed to reduce deaths or hospitalisation compared with usual care.
The National Clinical Evidence Taskforce issued a conditional recommendation against molnupiravir (Lagevrio) on Friday after weeks spent reviewing preliminary results from the UK-based PANORAMIC trial.
